Drugs / EBV-specific autologous CTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00063648 | May 2002 → Dec 2007 | liver disorder, post-transplant lymphoproliferative disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV-specific autologous CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00063648 ↗ |
| Modality | Cell therapy | “autologous adoptive EBV-specific CTL immunotherapy” NCT00063648 ↗ |